Literature DB >> 24214336

Serum uric acid is inversely proportional to estimated stroke volume and cardiac output in a large sample of pharmacologically untreated subjects: data from the Brisighella Heart Study.

Arrigo Francesco Giuseppe Cicero1, Martina Rosticci, Angelo Parini, Cristina Baronio, Sergio D'Addato, Claudio Borghi.   

Abstract

Serum uric acid is representative for xanthine-oxidase, the key enzyme involved in the production of uric acid, which is up-regulated in the failing heart, and may play an important role in the pathophysiologic process that leads to heart failure. In our study, we investigated the relation between stroke volume, cardiac output and serum uric acid in a large sample of overall healthy pharmacologically untreated subjects. The Brisighella Heart Study included 2,939 men and women between the ages of 14-84 without prior coronary heart disease or cerebrovascular disease who were not taking antihypertensive therapy at baseline. For this study, we selected 734 adult subjects enrolled in the last Brisighella population survey not taking antihypertensive, antidiabetic, lipid-lowering and uric acid-lowering drugs, and who were also not affected by chronic heart failure or by gout. The main predictors of cardiac functionality parameters were mean arterial pressure (MAP), HR, SUA and age (all p < 0.001), while gender, BMI, LDL-cholesterol, HDL-cholesterol, triglycerides, fasting plasma glucose, creatinine, estimated glomerular filtration rate, physical activity and smoking habit were not significantly associated (all p > 0.05). In particular, there is a strong relation between estimated cardiac output and serum uric acid (B = -0.219, p < 0.001) and between stroke volume and serum uric acid (B = -3.684, p < 0.001). These observations might have an impact on future considerations about serum uric acid as an early inexpensive marker of heart function decline in the general population.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24214336     DOI: 10.1007/s11739-013-1016-9

Source DB:  PubMed          Journal:  Intern Emerg Med        ISSN: 1828-0447            Impact factor:   3.397


  26 in total

Review 1.  Nitroso-redox interactions in the cardiovascular system.

Authors:  Jeffrey M Zimmet; Joshua M Hare
Journal:  Circulation       Date:  2006-10-03       Impact factor: 29.690

2.  Evaluation of the Vicorder, a novel cuff-based device for the noninvasive estimation of central blood pressure.

Authors:  Giacomo Pucci; Joseph Cheriyan; Annette Hubsch; Stacey S Hickson; Parag R Gajendragadkar; Timothy Watson; Michael O'Sullivan; Jean Woodcock-Smith; Giuseppe Schillaci; Ian B Wilkinson; Carmel M McEniery
Journal:  J Hypertens       Date:  2013-01       Impact factor: 4.844

3.  Serum uric acid levels correlate with filling pressures in systolic heart failure.

Authors:  Ahmad Amin; Farveh Vakilian; Majid Maleki
Journal:  Congest Heart Fail       Date:  2011-01-27

4.  The association between serum uric acid level and long-term incidence of hypertension: Population-based cohort study.

Authors:  A Shankar; R Klein; B E K Klein; F J Nieto
Journal:  J Hum Hypertens       Date:  2006-10-05       Impact factor: 3.012

5.  Absence of an independent association between serum uric acid and left ventricular mass in Caucasian hypertensive women and men.

Authors:  G Mulè; E Nardi; M Costanzo; M Mogavero; L Guarino; T Viola; M G Vario; V Cacciatore; G Andronico; G Cerasola; S Cottone
Journal:  Nutr Metab Cardiovasc Dis       Date:  2012-04-10       Impact factor: 4.222

Review 6.  Potential role of uric acid in metabolic syndrome, hypertension, kidney injury, and cardiovascular diseases: is it time for reappraisal?

Authors:  Zohreh Soltani; Kashaf Rasheed; Daniel R Kapusta; Efrain Reisin
Journal:  Curr Hypertens Rep       Date:  2013-06       Impact factor: 5.369

7.  Association of serum uric acid and cardiovascular disease in healthy adults.

Authors:  Shaye Kivity; Eran Kopel; Elad Maor; Fadi Abu-Bachar; Shlomo Segev; Yechezkel Sidi; David Olchovsky
Journal:  Am J Cardiol       Date:  2013-01-24       Impact factor: 2.778

8.  Association and interaction analysis of metabolic syndrome and serum uric acid on diastolic heart failure.

Authors:  Z-H Tang; Z Fang; F Zeng; Z Li; L Zhou
Journal:  J Endocrinol Invest       Date:  2013-02-12       Impact factor: 4.256

9.  Is uric acid itself a player or a bystander in the pathophysiology of chronic heart failure?

Authors:  Xu Duan; Feng Ling
Journal:  Med Hypotheses       Date:  2007-08-06       Impact factor: 1.538

10.  The xanthine oxidase inhibitor oxypurinol reduces cancer cachexia-induced cardiomyopathy.

Authors:  Jochen Springer; Anika Tschirner; Kai Hartman; Stephan von Haehling; Stefan D Anker; Wolfram Doehner
Journal:  Int J Cardiol       Date:  2013-06-14       Impact factor: 4.164

View more
  9 in total

1.  Uric acid and cardiac performance.

Authors:  Enzo Manzato
Journal:  Intern Emerg Med       Date:  2014-05-28       Impact factor: 3.397

Review 2.  Hyperuricemia and renal risk.

Authors:  Francesca Viazzi; Giovanna Leoncini; Elena Ratto; Roberto Pontremoli
Journal:  High Blood Press Cardiovasc Prev       Date:  2014-01-31

3.  Xanthine oxidase inhibitors in elderly patients with heart failure: useful or useless?

Authors:  Vivianne Presta; Barbara Citoni; Giuliano Tocci
Journal:  Intern Emerg Med       Date:  2019-05-13       Impact factor: 3.397

Review 4.  Fructose Intake, Serum Uric Acid, and Cardiometabolic Disorders: A Critical Review.

Authors:  Cristiana Caliceti; Donato Calabria; Aldo Roda; Arrigo F G Cicero
Journal:  Nutrients       Date:  2017-04-18       Impact factor: 5.717

Review 5.  Endothelial dysfunction in neuroprogressive disorders-causes and suggested treatments.

Authors:  Gerwyn Morris; Basant K Puri; Lisa Olive; Andre Carvalho; Michael Berk; Ken Walder; Lise Tuset Gustad; Michael Maes
Journal:  BMC Med       Date:  2020-10-19       Impact factor: 8.775

6.  Comparison between febuxostat and allopurinol uric acid-lowering therapy in patients with chronic heart failure and hyperuricemia: a multicenter randomized controlled trial.

Authors:  Satoshi Suzuki; Akiomi Yoshihisa; Tetsuro Yokokawa; Atsushi Kobayashi; Takayoshi Yamaki; Hiroyuki Kunii; Kazuhiko Nakazato; Akihiro Tsuda; Tatsunori Tsuda; Toshiyuki Ishibashi; Ichiro Konno; Osamu Yamaguchi; Hirofumi Machii; Naoki Nozaki; Takeshi Niizeki; Takuya Miyamoto; Yasuchika Takeishi
Journal:  J Int Med Res       Date:  2021-12       Impact factor: 1.671

7.  The Prognostic Impact of Serum Uric Acid on Disease Severity and 5-Year Mortality in Patients With Idiopathic Pulmonary Artery Hypertension.

Authors:  Lu Yan; Zhihua Huang; Zhihui Zhao; Qing Zhao; Yi Tang; Yi Zhang; Xin Li; Anqi Duan; Qin Luo; Zhihong Liu
Journal:  Front Med (Lausanne)       Date:  2022-01-26

8.  Uric acid and sodium-glucose cotransporter-2 inhibition with empagliflozin in heart failure with reduced ejection fraction: the EMPEROR-reduced trial.

Authors:  Wolfram Doehner; Stefan D Anker; Javed Butler; Faiez Zannad; Gerasimos Filippatos; João Pedro Ferreira; Afshin Salsali; Carolyn Kaempfer; Martina Brueckmann; Stuart J Pocock; James L Januzzi; Milton Packer
Journal:  Eur Heart J       Date:  2022-09-21       Impact factor: 35.855

9.  Uric Acid Impairs Insulin Signaling by Promoting Enpp1 Binding to Insulin Receptor in Human Umbilical Vein Endothelial Cells.

Authors:  Eliezer J Tassone; Antonio Cimellaro; Maria Perticone; Marta L Hribal; Angela Sciacqua; Francesco Andreozzi; Giorgio Sesti; Francesco Perticone
Journal:  Front Endocrinol (Lausanne)       Date:  2018-03-26       Impact factor: 5.555

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.